Physician profile
Anthony Morales
NPI 1871576215
$5,009.33
in general payments reported to CMS, 2019-2025
28 companies · $681 in 2025
The $681 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,178 · 2020: $673 · 2021: $392 · 2022: $397 · 2023: $1,007 · 2024: $681 · 2025: $681.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,358 · Education: $10.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,357.52 |
| Education | $10.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,517.12 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $541.81 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $519.10 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $272.74 | 2021-2023 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $265.48 | 2019-2025 | Eliquis, Camzyos |
| Abbott Laboratories | $256.30 | 2021-2025 | Aveir, Merlin@Home, Jot Dx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $225.07 | 2019-2024 | Jardiance |
| Amgen INC. | $209.40 | 2019-2025 | Repatha, Repatha |
| Esperion Therapeutics, INC. | $172.33 | 2021-2025 | Nexletol |
| Astrazeneca Pharmaceuticals Lp | $122.05 | 2019-2024 | Farxiga |
| Baxter Healthcare | $107.21 | 2024-2025 | Hillrom - Cardiac Ambulatory Monitor, Hillrom - Carnation Ambulatory Monitor |
| Irhythm Technologies, INC. | $89.89 | 2023-2024 | Zio Xt Patch, Zio Monitor |
| Kowa Pharmaceuticals America, INC. | $86.01 | 2019-2020 | |
| Lundbeck LLC | $83.18 | 2019-2020 | |
| Novo Nordisk INC | $77.56 | 2019-2024 | Ozempic |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $64.94 | 2021-2024 | |
| Daiichi Sankyo INC. | $56.43 | 2024 | Injectafer |
| Scpharmaceuticals INC. | $56.18 | 2023-2025 | |
| Gilead Sciences, INC. | $53.11 | 2019 | |
| Medtronic, INC. | $52.73 | 2021-2024 | Linq II |
| Kestra Medical Technology Services, INC. | $49.92 | 2025 | Assure Wcd |
| Sanofi-Aventis U.S. LLC | $23.30 | 2023 | |
| Philips North America LLC | $22.48 | 2025 | Ambulatory Monitoring & Diagnostics Undivided |
| Atricure, INC. | $22.12 | 2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $17.51 | 2023 | Lifevest |
| Inspire Medical Systems, INC. | $17.09 | 2025 | Inspire |
| Terumo Medical Corporation | $14.95 | 2019 | |
| Medtronic Vascular, INC. | $13.32 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Morales listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.